Canada’s free ride on U.S. drug development may end soon
A shift in U.S. drug pricing could cut pharmaceutical profits, meaning less money for research and development
Read MoreA shift in U.S. drug pricing could cut pharmaceutical profits, meaning less money for research and development
Read MoreThe system’s weak performance, rising costs, shifting demographics and a court challenge will all drive change
Read MoreA Fraser Institute study evaluated the quantity and quality of Canada’s freshwater and discovered just a few areas of concern
Read MoreCapital will flow to jurisdictions with attractive policies and, frankly, Canada’s investment climate is dismal
Read MoreWhen a province mandates a single curriculum, it eliminates diversity and experimentation that can lead to better methods
Read More